Writing stories of life

to advance science

News

17.01.2022 | Press Release

Neurimmune expands drug discovery collaboration with Ono Pharmaceutical in the field of neurodegenerative diseases

07.01.2022 | Press Release

Neurimmune enters into a collaboration and license agreement with AstraZeneca to develop and commercialize NI006

18.11.2021 | Press Release

Neurimmune and TVM Capital Life Science Announce the Initiation of AL-S Pharma’s Phase 2 Study of AP-101 for the Treatment of ALS

12.11.2021 | Company News

New aducanumab biomarker data show correlation between treatment effect on biomarkers and reduction in clinical decline

07.06.2021 | Press Release

Zulassung von Aducanumab durch die FDA

07.06.2021 | Press Release

FDA Approval of Aducanumab

26.05.2021 | Company News

Neurimmune Announces Publication in Nature Communications of its Experimental Therapy Targeting Transthyretin Amyloid

10.03.2021 | Company News

Neurimmune to Participate in AD/PD 2021 Virtual Conference on March 9-13, 2021

10.12.2020 | Company News

Neurimmune Welcomes Biogen’s News on the Filing of a New Drug Application for Aducanumab in Japan

30.10.2020 | Company News

Neurimmune Welcomes Biogen’s News on European Medicines Agency Acceptance of the Marketing Authorization Application for Aducanumab

21.09.2020 | Company News

Neurimmune welcomes NovaGo Therapeutics’ appointment of Ian Metcalfe as CEO

07.08.2020 | Company News

Neurimmune Welcomes Biogen’s News on FDA’s Acceptance of the Aducanumab BLA Filing with Priority Review

08.07.2020 | Company News

Neurimmune Welcomes Biogen’s News on the Submission of a Biologics License Application to FDA for Aducanumab

01.04.2020 | Press Release

Neurimmune and Ethris Sign Collaboration Agreement to Rapidly Develop Inhaled mRNA-based Antibody Therapy for the Treatment of Covid-19

27.02.2020 | Press Release

Neurimmune Announces the Initiation of a Phase 1 Study of NI006 for the Treatment of ATTR Cardiomyopathy

Your web browser is out of date

Update your browser for more security, speed and the best experience.

Update my browser Continue